BioSpace News Archive

Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, announced that management will present a company overview at the following investor conferences

Sol-Gel Technologies, Ltd., a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, announced financial results for the third quarter ended September 30, 2019 and provided an update on its clinical development programs.

Total Revenues for Third Quarter and First Nine Months of 2019 were $33.1 Million and $95.1 Million, Respectively, Compared to $15.0 Million and $66.3 Million in the Respective Periods in 2018.

Separation of Baudax Bio as Independent Company Expected to be Completed With Distribution on November 21, 2019

Avanos Medical, Inc. announced that Joe Woody, chief executive officer, will present at the Stifel 2019 Healthcare Conference in New York City on Wednesday, Nov. 20 at approximately 8 a.m., ET.

Intec Pharma Ltd. announces that Company management will participate in the Jefferies London Healthcare Conference..

AcelRx Pharmaceuticals, Inc. announced a publication analyzing pooled dosing and efficacy data from use of the sufentanil sublingual tablet 30 mcg among multiple demographic subgroups This data, published in the Journal of PeriAnesthesia Nursing, was analyzed to aid nurses in understanding the effectiveness and duration of action of SST 30 mcg in the management of moderate-to-severe acute pain across a variety of patient demographics.

LifeMax Laboratories, Inc. announced that the European Commission granted orphan drug designation to LM-030, an investigational therapy licensed from Novartis and ready to enter into a pivotal clinical trial for the treatment of Netherton Syndrome.

Aruna Bio, Inc., a leader in the development of neural exosomes for the treatment of neurodegenerative diseases, announced the appointment of Renee Boerner, PhD, as Vice President of Regulatory Affairs.

ArQule, Inc. announced that Paolo Pucci, Chief Executive Officer, will participate in the Jefferies London Healthcare Conference on Wednesday, November 20, 2019 in London, UK.